Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term mesothelioma. Found 16 abstracts

Barbarino M, Cesari D, Intruglio R, Indovina P, Namagerdi A, Bertolino FM, Bottaro M, Rahmani D, Bellan C, Giordano A. Possible repurposing of pyrvinium pamoate for the treatment of mesothelioma: A pre-clinical assessment. Journal of cellular physiology. 2018 Sep;233(9):7391-401.
Sementino E, Menges CW, Kadariya Y, Peri S, Xu J, Liu Z, Wilkes RG, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. Inactivation of Tp53 and Pten drives rapid development of pleural and peritoneal malignant mesotheliomas. Journal of cellular physiology. 2018 Nov;233(11):8952-61.   PMCID: PMC6168364
Cheung M, Testa JR. BAP1, a tumor suppressor gene driving malignant mesothelioma. Translational lung cancer research. 2017 Jun;6(3):270-8.   PMCID: PMC5504107
Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck M, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant Pleural Mesothelioma. Journal of the National Comprehensive Cancer Network. 2012 Jan;10(1):26-41.   PMCID: not NIH funded
Menges CW, Sementino E, Talarchek J, Xu JF, Chernoff J, Peterson JR, Testa JR. Group I p21-Activated Kinases (PAKs) Promote Tumor Cell Proliferation and Survival through the AKT1 and Raf-MAPK Pathways. Molecular Cancer Research. 2012 Sep;10(9):1178-88.   PMCID: PMC3447107
Shukla A, Barrett TF, MacPherson MB, Hillegass JM, Fukagawa NK, Swain WA, O'Byrne KJ, Testa JR, Pass HI, Faux SP, Mossman BT. An Extracellular Signal-Regulated Kinase 2 Survival Pathway Mediates Resistance of Human Mesothelioma Cells to Asbestos-Induced Injury. American Journal of Respiratory Cell and Molecular Biology. 2011 Nov;45(5):906-14.   PMCID: PMC3262687
Shukla A, Hillegass JM, MacPherson MB, Beuschel SL, Vacek PM, Butnor KJ, Pass HI, Carbone M, Testa JR, Heintz NH, Mossman BT. ERK2 is essential for the growth of human epithelioid malignant mesotheliomas. International journal of cancer. 2011 Sep;129(5):1075-86.   PMCID: PMC3071888 [available 2012/5/12]
Ivanov SV, Miller J, Lucito R, Tang CL, Ivanova AV, Pei JM, Carbone M, Cruz C, Beck A, Webb C, Nonaka D, Testa JR, Pass HI. Genomic events associated with progression of pleural malignant mesothelioma. International journal of cancer. 2009 Feb;124(3):589-99.   PMCID: PMC2933144
Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, Mossman BT. Cellular and molecular parameters of mesothelioma. Journal of cellular biochemistry. 2006 Jul;98(4):723-34.
Altomare DA, You HH, Xiao GH, Ramos-Nino ME, Skele KL, De Rienzo A, Jhanwar SC, Mossman BT, Kane AB, Testa JR. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth. Oncogene. 2005 Sep 08;24(40):6080-9.
Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, Jhanwar S, Testa JR. The NF2 tumor suppressor gene product, merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Molecular and Cellular Biology. 2005 Mar;25(6):2384-94.
Lee WC, Testa JR. Somatic genetic alterations in human malignant mesothelioma (Review). International Journal of Oncology. 1999 Jan;14(1):181-8.
Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Journal of cellular physiology. 1999 Aug;180(2):150-7.
Sauter ER, Langer C, Coia LR, Goldberg M, Keller SM. Optimal Management of Malignant Mesothelioma after Subtotal Pleurectomy - Revisiting the Role of Intrapleural Chemotherapy and Postoperative Radiation. Journal of surgical oncology. 1995 Oct;60(2):100-5.
Soler AP, Knudsen KA, Jaurand MC, Johnson KR, Wheelock MJ, Kleinszanto AJ, Salazar H. The Differential Expression of N-Cadherin and E-Cadherin Distinguishes Pleural Mesotheliomas from Lung Adenocarcinomas. Human Pathology. 1995 Dec;26(12):1363-9.
Jin Quan C, Jhanwar SC, You Yong L, Testa JR. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Research. 1993 Jan;53(20):4761-3.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term mesothelioma

mesothelioma asbestos pleural mesothelioma gene-expression nf2 gene comparative genomic hybridization growth-factor-receptor malignant mesothelioma multiple regions Bap1 merlin activation AKT protein extrapleural pneumonectomy pleural simian-virus-40 phosphorylation signal-regulated kinases loss of heterozygosity GENE-EXPRESSION human cancers bilateral acoustic neurofibromatosis targets plakoglobin in-vivo cells malignant pleural dose hemithoracic radiation chemotherapy induced apoptosis states sv40 fas ligand time to progression neurofibromatosis type-2 study-group trial monoclonal- Homozygote large-t-antigen ras as an expert witness in a case involving the role of inherited occasion receptor MICROARRAY ANALYSIS uvomorulin p53 controlled-trial p16 multicenter phase-ii cell-adhesion molecule Cell Biology diffuse epithelial mesothelioma gamma-glutamylcysteine synthetase on BAP1 genetic screening adjuvant therapy human NF2 localization growth insulation workers akt potentiating factor human-malignant mesothelioma gene expression 1993 guchi t-cancer research-v53-p4349 CGH EXPRESSION phosphatidylinositol 3-kinase apoptosis dna-binding activity SV40 mitogen-activated protein kinases tumor-suppressor gene Biochemistry & Molecular Biology intensity-modulated radiotherapy regulated kinase megakaryocyte cancer expression homozygous deletions akt activation oncogenes interferon genes kinase N-CADHERIN e-cadherin protein kinase B tumor suppressor HUMAN-CHROMOSOME 3P213 mTOR tumor suppressors tumor suppressor genes factor scatter factor chromosome abnormalities chromosomal-abnormalities nitric-oxide synthase PROGNOSTIC-FACTORS mutations of BAP1 in mesothelioma Both authors have a pending patent application Human Chromosomes-Pair 9 ovarian-cancer randomized extracellular signal-regulated kinase (ERK1 pemetrexed plus cisplatin kinase-b copy number changes NCCN Guidelines epidermal growth factor receptor antibody genomic instability tumor angiogenesis map kinase 6q malignant pleural mesothelioma prostate intraepithelial neoplasia human schwannoma cells trimodality therapy radiation therapy NCCN Clinical Practice Guidelines surgery HOMOZYGOUS DELETION REGION toxicity ONCOSTATIN-M ROMA fibers n-cadherin copy number alterations 2) positron-emission-tomography inhibitor Wnt asbestos-induced diseases pleural effusion c-met transformation TUMOR-SUPPRESSOR ARRAY-CGH DATA cancers expanded access program pak overall survival LUNG-CANCER beta-catenin united- Pten critical region antisense expression plasmid pyrvinium pamoate cancer-cells
Last updated on Wednesday, February 05, 2020